Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol

With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients